At the 2018 American Association for Cancer Research (AACR) Annual Meeting earlier this month in Chicago, Dr. Matthew Hellmann presented the results of the immunotherapy drug combo of Nivolumb (Opdivo) and Ipilmumab (Yervoy). This drug combo improved progression of disease for a select group of patients with advanced lung cancer that had a number of genetic mutations. The study looked at patients’ tumor mutation burden, a measure of flaws to their cancer genes, and found that of the 679 patients, 299 had a high mutation burden. For those patients, survival without progression of disease was 43% at one year for those on the immunotherapy combo, compared to 13% for those on standard chemotherapy. The median time until progression of disease was 7 months for the immunotherapy combo, compared to 5.5 months for chemotherapy. Medicare recently agreed to cover the $3,000 profiling test for advanced cancer. “We have a tool that helps us determine who are the patients that are most likely to benefit from this combination,” Hellmann said.